Your browser doesn't support javascript.
Long-Circulating Amphiphilic Doxorubicin for Tumor Mitochondria-Specific Targeting.
Artigo em Inglês | MEDLINE | ID: mdl-30479120
The mitochondria have emerged as a novel target for cancer chemotherapy primarily due to their central roles in energy metabolism and apoptosis regulation. Here we report a new molecular approach to achieve high levels of tumor- and mitochondria-selective delivery of the anticancer drug doxorubicin. This is achieved by molecular engineering which functionalizes doxorubicin with a hydrophobic lipid tail conju-gated by a solubility-promoting polyethylene glycol polymer (amphiphilic Doxorubicin or amph-DOX). In vivo, the amphiphile conjugated to doxorubicin exhibits a dual function: i) it binds avidly to serum albumin and hijacks albumin's circulating and transporting pathways, resulting in prolonged circulation in blood, increased accumulation in tumor, and reduced exposure to the heart; ii) it also redirects doxorubicin to mi-tochondria by altering the drug molecule's intracellular sorting and transportation routes. Efficient mito-chondrial targeting with amph-DOX causes a significant increase of reactive oxygen species (ROS) levels in tumor cells, resulting in markedly improved antitumor efficacy than the unmodified doxorubicin. Am-phiphilic modification provides a simple strategy to simultaneously increase the efficacy and safety of doxorubicin in cancer chemotherapy.





Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Idioma: Inglês Assunto da revista: Biotecnologia / Engenharia Biomédica Ano de publicação: 2018 Tipo de documento: Artigo